Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

OBJECTIVES: This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy/safety in patients with active psoriatic arthritis (PsA). METHODS: Data were pooled from two phase 3 studies (NCT01877668; NCT01882439). Analyses included patients randomised to tofacitinib 5/10 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Giles, Jon T, Ogdie, Alexis, Gomez-Reino, Juan J, Helliwell, Philip S, Germino, Rebecca, Stockert, Lori, Young, Pamela, Joseph, Wael, Mundayat, Rajiv, Graham, Daniela, Ritchlin, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813423/
https://www.ncbi.nlm.nih.gov/pubmed/33452181
http://dx.doi.org/10.1136/rmdopen-2020-001486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813423/
https://www.ncbi.nlm.nih.gov/pubmed/33452181
http://dx.doi.org/10.1136/rmdopen-2020-001486

Ejemplares similares